Carbamazepine: uses, genetic safety (HLA), and drug interactions

Overview

Carbamazepine (CBZ) is a dibenzazepine anticonvulsant and mood-stabiliser that has been in clinical use since the 1960s. Its primary mechanism is voltage-gated sodium channel blockade in neuronal membranes, which suppresses the propagation of epileptic discharges. Beyond epilepsy, CBZ is established treatment for neuropathic pain and certain psychiatric conditions. Understanding its pharmacological peculiarities—above all, its powerful enzyme-inducing properties—is essential for safe use.

One of CBZ's most clinically important characteristics is its induction of hepatic cytochrome P450 enzymes, particularly CYP3A4. This accelerates the metabolism of many co-prescribed drugs and of CBZ itself—a phenomenon called autoinduction. During the first 2–4 weeks of therapy, CBZ plasma levels fall substantially as autoinduction develops, so dose re-titration is often necessary. Awareness of this process helps explain why initial symptom control may wane before a stable therapeutic level is achieved.

Indications

Carbamazepine is indicated for focal (partial) seizures—with or without secondary generalisation—and for tonic-clonic (Grand Mal) seizures. It is not recommended for absence epilepsy or juvenile myoclonic epilepsy (JME), where it may paradoxically worsen seizure control. Accurate epilepsy-syndrome classification by a neurologist is therefore mandatory before prescribing CBZ; using it in the wrong epilepsy type causes harm. The usual starting dose is 100–200 mg once or twice daily, titrated over several weeks to the effective maintenance dose of 400–1200 mg/day in divided doses.

Trigeminal neuralgia—characterised by paroxysmal, electric-shock-like facial pain—is one of CBZ's most well-established indications, where it is considered first-line therapy. CBZ is also used in other neuropathic pain syndromes and as a mood stabiliser in bipolar disorder, particularly in patients who have an inadequate response to or cannot tolerate lithium. In psychiatric use, CBZ is typically reserved for specialist initiation and requires close monitoring.

HLA & genetic safety

Carbamazepine is associated with a rare but potentially fatal cutaneous adverse reaction: Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). These immune-mediated hypersensitivity reactions—involving extensive epidermal detachment, mucosal involvement, and potential multi-organ failure—can appear within the first two weeks of therapy and carry mortality rates of 10–30%. The reactions are largely irreversible once established, making prevention paramount.

Large pharmacogenomic studies, originating largely from Taiwan and subsequently replicated across Asia, demonstrated that the HLA-B*15:02 allele is a strong predictor of CBZ-induced SJS/TEN. This allele is carried by 6–8% of Han Chinese, ~8% of Thai people, ~6% of Malaysians, and ~2–3% of South Asians; the prevalence in populations of European or Iranian origin is considerably lower. The US FDA and multiple international regulatory bodies now recommend HLA-B*15:02 screening before initiating CBZ in patients of Asian ancestry.

A second allele, HLA-A*31:01, is associated with less severe but still clinically significant hypersensitivity reactions (maculopapular exanthem, drug reaction with eosinophilia and systemic symptoms) predominantly in European and Japanese populations. Results of HLA testing should be reviewed with the prescribing physician. The decision to initiate or continue CBZ must weigh clinical benefit against genetic risk and is ultimately a specialist judgement. A negative test does not eliminate all SJS risk; vigilance for cutaneous symptoms remains necessary regardless.

Drug interactions

Carbamazepine is one of the most potent inducers of cytochrome P450 enzymes (CYP3A4, CYP2C9, CYP2C19) and P-glycoprotein in clinical medicine. This means CBZ accelerates the metabolism of a very large number of co-prescribed drugs, often reducing their plasma concentrations to subtherapeutic levels. Key interactions include:

Oral anticoagulants: CBZ substantially lowers warfarin and direct oral anticoagulant (DOAC) levels, compromising anticoagulation. Frequent INR monitoring and dose adjustment are required. Antiretrovirals: Many HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors have serious pharmacokinetic interactions with CBZ; co-prescription generally requires specialist review. Other antiseizure medicines: Levels of phenytoin, lamotrigine, topiramate, and valproate may all be altered; effects are bidirectional. Hormonal contraceptives: CBZ reduces oestrogen and progestogen levels, abolishing contraceptive efficacy. Non-hormonal contraception or specialist-guided alternative methods are required.

Conversely, some drugs raise CBZ levels, risking toxicity: erythromycin and clarithromycin, isoniazid, azole antifungals, some calcium channel blockers, and certain antidepressants. Toxic signs of elevated CBZ include diplopia, ataxia, nausea, vomiting, and confusion. Always provide a complete and updated medication list—including supplements and herbal preparations—to every prescriber and pharmacist you see.

Monitoring

Standard monitoring during CBZ therapy includes: complete blood count (aplastic anaemia and agranulocytosis are rare but serious), liver function tests (hepatotoxicity is uncommon but reported), and serum sodium (hyponatraemia due to SIADH-like effect occurs in up to 5% of patients, particularly the elderly). Measurement of plasma CBZ levels is recommended when seizures are not controlled, signs of toxicity appear, non-adherence is suspected, or significant drug interactions occur. Therapeutic plasma concentrations are generally 4–12 mg/L.

Seek emergency care immediately for: any rash—even initially mild—especially if accompanied by fever, mucosal lesions, or eye pain; mouth sores or eye redness; jaundice; unusual bleeding or bruising; new or worsening seizures; and severe dizziness, imbalance, or double vision that correlates with a dose change. These signs may herald serious, rapidly progressive adverse reactions where early intervention is life-saving.

Summary

With appropriate genetic screening, structured monitoring, and careful management of drug interactions, carbamazepine can be both effective and safe. Patient awareness of warning signs, adherence to prescribed dosing schedules, avoidance of abrupt discontinuation (which can precipitate rebound seizures), and coordination of all medication changes through the treating team are the pillars of successful long-term therapy. Treat any new skin, mucosal, or systemic symptom as a potential warning sign and seek prompt medical attention.